The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thanks Enslin...odd...when will present working capital run out? Can't see Baxter writing off £10million or so inestment when all appears to be going well with trials
Do we have to swap emails all day or will some kind investor post a precis of the phone in? Thanks
Happy New Year everybody. Your lordship will notice that my moniker appears already on that board, not much going on but at least we all have a home to go to.I notice there is an Elmer already registered and a Mr Madoff with a joke on the board....that wouldn't be our resident jokester Mr Leeson in disguise would it?? Anyway good luck all and again, let us hope this is our year
just sign up for an email alert...simples....works for me http://seekingalpha.com/symbol/XBIO
Well perhaps it's time to have some decent PR
Good post Lordy. I am sure that with some timely release of trial news, such share issuance would generate sufficient interest to get XBIO on US investors' radar, prior to a NASDAQ move.
I suspect it will be a bit of both - Nasdaq and debt. Certainly I am liking the way it is going. No doubt it will be on the back of further good trial results to give a new baseline for the Nasdaq float
Indeed we are! All looking good I would say, steady as she goes
LEXINGTON, Mass., June 11, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announced today that its partner, the Serum Institute of India, has dosed the first patient in the second cohort of a Phase 2a clinical, sequential single dose study of intravenously (IV) administered ErepoXen® (PSA EPO) for the treatment of anemia in Chronic Kidney Disease (CKD) patients on dialysis. "We are very pleased to continue progressing the development of ErepoXen®, our most advanced product candidate," said Scott Maguire, Chief Executive Officer of Xenetic. "This Serum Institute-run trial represents our third study of the compound, and joins other trials currently underway in Australia, New Zealand and Russia, where we are holding ICH Compliant and Russian studies of the compound, respectively. We are pleased with the success of our earlier Phase 2 subcutaneous PSA-EPO trials in India, and look forward to working with our international partners to continue developing ErepoXen® as a potential treatment option for anemic patients in need of more effective therapies. With this IV trial, we now cover the two forms of administration for EPO in renal compromised patients, a global market worth over $7 billion. " ErepoXen® is an improved, polysialylated form of erythropoietin (EPO), a hormone produced by the kidneys to maintain red blood cell production and prevent anemia. ErepoXen® is designed to reduce the required frequency of dosage and side effects, and to be less immunogenic than existing treatments. In the second cohort of the Phase 2a trial, patients will start with a single ErepoXen® dose of 1.5 mcg/kg body weight. The patient's pharmacodynamic, pharmacokinetic and immunogenic parameters are then followed for the next 28 days. Dose levels in escalating form will then be administered. Safety and experimental parameters will be examined at the end of each dosing cohort before moving onto the next level. The first cohort of patients at the lowest dose level has been finished. The total cost of this India-based trial is being borne by the Serum Institute. This open-label intravenous trial follows the successful completion of two subcutaneous ErepoXen® clinical trials in India, and is designed to determine the maximum tolerated single dose of ErepoXen®. The first was a Phase 1 single dose range finding study for subcutaneously administered PSA-EPO in healthy volunteers. The second was a Phase 2 single dose range finding study for subcutaneously administered PSA-EPO in CKD patients not on dialysis. There have been no serious adverse events attributable to PSA-EPO reported thus far in over 130 subjects dosed to date.
LEXINGTON, Mass., Jun 09, 2014 (GLOBE NEWSWIRE via COMTEX) -- Xenetic Biosciences, Inc. /quotes/zigman/27724288/delayed/quotes/nls/xbio XBIO +16.67% , a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,735,557, entitled "Activated Sialic Acid Derivatives for Protein Derivatization and Conjugation," with claims that cover lead compound, ErepoXen®, and Xenetic's broader polysialic acid technologies. "This newly issued patent further fortifies and extends our robust patent portfolio covering the PolyXen® delivery technology platform, including our lead product candidate, ErepoXen®," said Scott Maguire, Chief Executive Officer of Xenetic. "This patent is one of thirteen patents allowed or issued in the last three months, and demonstrates Xenetic's recent efforts to protect our broad and unique intellectual property both domestically and abroad. We now have over 140 issued patents that serve as the foundation for our drug developments."
Well, net resut is to send the SP down to 55 cents!
Higher than usual volume today over the pond Lordy. back up to 85c,
Mmm.. I have a question on that. They have no place in Xenetics technology platform do they at the moment? can somebody confirm, can't find anything myself, but would like confirmation. Cheers
I await his Lordship's response.....we must be at the end of your joke book with that one, surely!!
Received mine yesterday in the post. I'm in no rush to set an account up, as the US riches from this share are at least a year off. Can't really imagine anyone wanting to sell in next 6 months or so. Suspect that peeps just want to see an improved share price just because we are now in the States. Patience will be very well rewarded here I suspect, following steady news flow leading up to Nasdaq and further progress beyond. Cheers to all.
There continues to be steady chunky buying. No doubt there will be a stream of managed newsflow throughout 2014 to improve prospects of an easy and successful move to a higher trading platform once in the US. Can't help feeling that some people are already "in the know"
This is from Hargreaves Lansdown Can I hold GSL Shares in my Hargreaves Lansdown portfolio? GSL is a US Company currently in the process of disposing of its existing business. GSL Shares are available for quotation on the Over-the-counter (OTC) Markets in the US. However, there has been limited trading in the Shares in recent times and the Shares are not considered to have a public valuation or market. GSL Shares will be issued in US Certificated Form only and will not be capable of being held or settled in the UK Settlement system, Crest. Additionally, as the Shares are only quoted on the OTC Markets in the US and are classed as a Micro-Cap Security, it will not be possible for us to hold the Shares via our US custodian. As a result Hargreaves Lansdown will be unable to hold or trade GSL Shares. What are my options? Option 1 - Sell your Xenetic Shares before the Scheme becomes effective. In light of the Scheme of Arrangement, Hargreaves Lansdown is offering a special commission free dealing facility on sales of Xenetic Shares given over the telephone or by post. To sell your Shares please contact our Dealers on 0117 980 9800. Please note that although Hargreaves Lansdown will endeavour to sell your Shares it may not be possible to sell all, or even any, of your Shares if a market for the Shares no longer exists.
Can't buy on HL without ringing the broker direct, never wavered here especially after news of the move to US first broke
Cheers Lordy, got to be a bargain haven't they, but DYOR etc
Hi Lordy, could you remind us all when our last chance to purchase these on AIM is. Cheers